FREE Daily Stock Alerts From Stock-PR.com
Orofino Gold Corp. has several Gold development properties in Colombia, a current hot spot of gold production in the world markets.
ORFG is please to announce that the Board Of Directors have appointed Mr. Ning Shi Long as Chairman of the Board and Executive Director.
Mr. Ary Fernando Pernett Marque has been appointed as the new President/CEO & Executive Director of Orofino Gold Corp. See full resume on ORFG's website.
Mr. Pernett will be responsible for all affairs of ORFG in Colombia. Mr. Pernett has 30 years of experience working in the Colombian Mining sector and will over the near term choose his new development team to assist in the development of the company’s Senderos de Oro gold camp in the Sur de Bolivar Colombia.
ORFG and Mr. Pernett will continue to work with Contexto Legal of Medellin and Bogota, ORFG ’s legal counsel as well as Discovery Consultants, (The Qualified 43-101 team) Canada, as they have in the past. The new team will now aggressively pursue other known Gold occurrences in the companies Senderos de Oro Gold Camp while the development team works to improve production at La Azul Mine.
The Board of Director’s have accepted resignation of John T. Martin, former Managing Director of the Company. His resignation is effective immediately. ORFG wish him well and success in future endeavors.
Douglas Lake Minerals Inc. (OTC:DLKM)
Douglas Lake Minerals Inc. has filed a Canadian National Instrument 43-101 Standards for Disclosure of Mineral Projects (”NI 43-101) Technical Report (the “Technical Report”) for its Handeni Project. DLKM’s 100% owned Handeni Project consists of four prospecting licenses covering approximately 800 square kilometers in the newly developing goldfields of Eastern Tanzania. Douglas Lake filed the Technical Report with the British Columbia Securities Commission via the System for Electronic Document Analysis and Retrieval (SEDAR).
The Technical Report was prepared by Dr. Reyno Scheepers, Ph.D., Pr.Sci.Nat., a South African based consulting geologist and a director of DLKM who fulfills the requirements to be a ‘Qualified Person’ for the purposes of NI 43-101.
“The scale of work covered by the Technical Report has significantly advanced Douglas Lake’s Handeni Project,” Harp Sangha, Chief Executive Officer comments, “We now have a number of very exciting gold targets which we are a priority for us to follow up with further exploration in 2011.”
The Technical Report details the results of exploration activities conducted by IPP Resources, the previous holding company of the area. Extensive geophysical and geologic work was conducted over several field seasons from 2008. The work included prospecting, rock and soil sampling, and a ground magnetic survey. All geochemical analytical work was conducted by internationally accredited labs, SGS Laboratories and/or Humac Laboratories in Mwanza, Tanzania.
RXi Pharmaceuticals Corporation (Nasdaq:RXII) Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT.ob), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. (www.antigenexpress.com), and RXi Pharmaceuticals Corporation (www.rxipharma.com) (NasdaqCM: RXII), a recognized leader in RNAi-based therapeutics, announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.
RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including its core focus of developing treatments for anti-scarring and retinal disorders.
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) announced that the Tel-Aviv Stock Exchange ("TASE") has approved the inclusion of the company's ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA and Biomed beginning on January 9, 2011. The shares will be added to the indexes under the "fast track" for adding shares to the Tel Aviv Stock Exchange's indexes.
Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders.
Mattson Technology Inc. (Nasdaq:MTSN) provided preliminary financial information for the Company's fourth quarter ended December 31, 2010. The Company expects to report results for the fourth quarter and the completed fiscal year in early February 2011. Due to a delay in the shipment of several tools scheduled for DRAM customers, net revenue for the fourth quarter is expected to be approximately $41 million. The Company's fourth quarter guidance, established October 20, 2010, was $46 million to $50 million. Third quarter net revenue was $39.8 million. The delay in tools sold to DRAM customers caused a change in the mixture of tool types shipped. The Company therefore expects gross margin for the fourth quarter to be significantly below the previously announced range of 36 percent to 39 percent. Similarly, net loss per share is expected to be significantly greater than the previously announced range of ($0.04) to $0.00.
Mattson Technology, Inc. designs, manufactures, and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits for the semiconductor manufacturing industry worldwide. It offers dry strip and rapid thermal processing equipment, and isotropic and low aspect ratio reactive ion.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 500,000 shares of 144 stock in Orofino Gold Corp. (PINK SHEETS: ORFG) valued at sixty five thousand dollars, and 500,000 shares of free trading shares valued at sixty five thousand dollars from a third party (QU CUI You) for 30 days advertising.
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.